-
Kalaris Therapeutics (KLRS) Misses Q3 EPS by 64c
-
Raymond James Defends Kalaris (KLRS) Amid 3pct Drop: 'We continue to like this set up and recommend purchase'
-
Citizens Starts Kalaris (KLRS) at Market Outperform
-
Kalaris Therapeutics (KLRS) Misses Q2 EPS by 61c
-
Piper Sandler Assumes Kalaris (KLRS) at Neutral
-
William Blair Reiterates Outperform Rating on Kalaris (KLRS)
-
Leerink Partners Starts Kalaris (KLRS) at Outperform
-
William Blair Starts Kalaris (KLRS) at Outperform
-
Kalaris Therapeutics (KLRS) Appoints Leone Patterson as Chair of Audit Committee
-
Kalaris Therapeutics (KLRS) Closes Merger with AlloVir

